DTC Act of 2025
- Sponsor
- Rep. Taylor, David J. [R-OH-2]
- Committees
- Ways and Means Committee (primary)
- Last action
- Jun 5, 2025
Bottom line
The bill aims to increase transparency in prescription drug pricing by requiring WAC disclosure in DTC advertisements, potentially influencing consumer choices and drug spending.
What it actually does
This bill, the "Drug-price Transparency for Consumers Act of 2025," mandates that direct-to-consumer (DTC) advertisements for prescription drugs and biological products include a clear disclosure of the wholesale acquisition cost (WAC) for a 30-day supply or typical course of treatment. It exempts drugs with a WAC under $35 and authorizes the Secretary of Health and Human Services to issue regulations for the visual and audio presentation of this information and to impose civil money penalties for non-compliance.
Proponents argue
Proponents argue that requiring price transparency in drug advertisements empowers consumers to make more informed healthcare decisions, reduces wasteful spending on expensive drugs when cheaper alternatives exist, and fosters greater competition in the pharmaceutical market. They cite evidence that DTC advertising inflates demand for costly brand-name drugs and that consumers often underestimate out-of-pocket costs, leading to prescriptions that patients cannot afford to fill.
Opponents contend
Opponents, typically pharmaceutical manufacturers, might argue that disclosing WAC in advertisements could confuse consumers, as the WAC is not necessarily what an individual patient pays due to insurance coverage. They may also contend that such requirements could stifle innovation by reducing the effectiveness of advertising, which is crucial for informing patients and physicians about new treatments. Additionally, they might argue it imposes an undue regulatory burden and could lead to patients avoiding necessary medications due to perceived high costs.
The bill is relatively short and its core provisions are straightforward, making it accessible for a reader to evaluate within a reasonable timeframe.
Section 3, adding new section 1150D(a) to Title XI of the Social Security Act.
Mandatory Disclosure of Wholesale Acquisition Cost (WAC) in Direct-to-Consumer Advertisements
This provision requires that by July 1, 2026, all direct-to-consumer advertisements for prescription drugs and biological products that are covered by Medicare or Medicaid and are required to disclose side effects, must also clearly show the wholesale acquisition cost (WAC) for a 30-day supply or a typical course of treatment. This aims to provide consumers with baseline cost information at the point of advertising.
Supporters argue
Supporters argue this provision directly addresses the information asymmetry in drug pricing, allowing consumers to understand the baseline cost of a drug before discussing it with their doctor. This transparency is expected to lead to more cost-conscious decisions and potentially lower overall drug spending.
Critics contend
Pharmaceutical manufacturers may argue that WAC is not representative of what most patients actually pay due to insurance, and its prominent display could deter patients from seeking necessary treatments, leading to poorer health outcomes. They might also claim it adds an unnecessary burden to advertising.
Tradeoffs
The provision balances the goal of consumer price transparency with concerns about potential patient confusion or reluctance to pursue treatment due to a high list price that may not reflect their out-of-pocket cost.
Section 3, adding new section 1150D(a)(2) to Title XI of the Social Security Act.
Exemption for Drugs with Wholesale Acquisition Cost Below $35
This provision creates an exception to the disclosure requirement for prescription drugs or biological products where the wholesale acquisition cost (WAC) for a 30-day supply (or typical course of treatment) is less than $35. This means lower-cost drugs would not need to include the WAC in their advertisements, focusing the regulatory effort on higher-cost medications.
Section 3, adding new section 1150D(c) to Title XI of the Social Security Act.
Secretary of HHS Rulemaking Authority for Disclosure Requirements
This provision directs the Secretary of Health and Human Services to issue final regulations within one year of the bill's enactment. These regulations will specify how the WAC information must be presented in both visual and audio components of direct-to-consumer advertisements across different media, and establish a timeframe for manufacturers to update ads when the WAC changes, ensuring consistent and effective disclosure.
Section 3, adding new section 1150D(d) to Title XI of the Social Security Act.
Civil Money Penalties for Violations
This provision establishes a civil money penalty of up to $100,000 for each violation by a manufacturer or their agent who fails to comply with the WAC disclosure requirement. It also specifies that existing provisions for civil money penalties under section 1128A of the Social Security Act will apply, ensuring a robust and established framework for enforcement.